This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
1 Primary · 13 Secondary · Reporting Duration: Randomization to date of death, due to any cause, up to 87 months from first subject in
1075 Total Participants · 3 Treatment Groups
Primary Treatment: Dato-DXd in combination with Durvalumab · No Placebo Group · Phase 3
Age 18 - 130 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: